Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)HKSE:02161 86 Gross Margin % is 52.33% as of Mar. 2026, which is 0% above its 10-year median of 52.14. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, JBM (Healthcare) ranks better than 62.78% on this metric.
The historical rank and industry rank for JBM (Healthcare)'s Gross Margin % or its related term are showing as below:
HKSE:02161'
s Gross Margin % Range Over the Past 10 Years
Min: 39.5 Med: 52.14 Max: 55.78
Current: 55.78
During the past 9 years, the highestGross Margin % of JBM (Healthcare) was 55.78%. The lowest was 39.50%. And the median was 52.14%.
HKSE:02161's Gross Margin % is ranked better than 62.78% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs HKSE:02161: 55.78
JBM (Healthcare) had a gross margin of 52.33% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for JBM (Healthcare) was 4.90% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
JBM (Healthcare) had a gross margin of 52.33% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
JBM (Healthcare) Gross Margin % Related Terms
JBM (Healthcare) Gross Margin % Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Gross Margin % distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
JBM (Healthcare) (HKSE:02161) has a Gross Margin % of 52.33% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on JBM (Healthcare) and its competitors. This is near median its historical median of 52.14. Over the past decade, JBM (Healthcare)'s Gross Margin % has ranged from 39.50 to 55.78. According to the industry distribution chart, JBM (Healthcare) ranks #351 out of 943 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is JBM (Healthcare)'s Gross Margin % too high?
JBM (Healthcare)'s current Gross Margin % of 52.33% is near median its 10-year median of 52.14. Over the past 10 years, this metric has ranged from a low of 39.50 to a high of 55.78. The Drug Manufacturers industry median Gross Margin % is 48.54. JBM (Healthcare)'s value of 52.33% is 7.8% above this industry median. Based on the distribution chart, JBM (Healthcare) ranks #351 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #351 out of 943 companies for Gross Margin %. This puts JBM (Healthcare) in the upper half of its industry. The industry median Gross Margin % is 48.54. JBM (Healthcare)'s value of 52.33% is 7.8% above this benchmark. Historically, JBM (Healthcare)'s own Gross Margin % has ranged from 39.50 to 55.78 over the past decade. While the company's 10-year median is 52.14 vs. the industry median of 48.54, JBM (Healthcare) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JBM (Healthcare)'s current Gross Margin % of 52.33% is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current Gross Margin % is 52.33%, which is near median its own 10-year median of 52.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.94 — trading 6.7% below its estimated fair value. The current Gross Margin % is 52.33%, which is near median its 10-year median of 52.14 and 7.8% above the Drug Manufacturers industry median of 48.54. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Gross Margin % is 52.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.94 is trading 6.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
Gross Margin %: 52.33% (near median its 10-year median of 52.14)
GF Value™: HK$2.08 vs. price of HK$1.94 (6.7% below fair value)
Industry Position: 7.8% above the Drug Manufacturers median (#351 of 943)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
